Nh Investment And Securities 1p (005945 KO) stock market data APIs
₩17967.622
438(2.4%)
as of November 4, 2025
Try our APIs with
free plan!
Nh Investment And Securities 1p Financial Data Overview
Price chart is built with
Anychart
NH Investment & Securities Co., Ltd. engages in the wealth management, investment banking, trading, and equity sales businesses in South Korea and internationally. The company offers debt capital market and equity capital market solutions. NH Investment & Securities Co., Ltd. was formerly known as Woori Investment & Securities Co., Ltd. and changed its name to NH Investment & Securities Co., Ltd. in December 2014. The company was incorporated in 1969 and is based in Seoul, South Korea. NH Investment & Securities Co., Ltd. is a subsidiary of NongHyup Financial Group Inc.
Prev. Close
17967.622
Open
18405.6232
High
18405.6232
Low
17938.9219
52 wk Range
10793.8739-20250
Market Cap
7 494 435 M
Shares Outstanding
18 871 K
Revenue
9 059 961 M
Dividends (Yield)
0.0542
Beta
0.637
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nh Investment And Securities 1p data using free add-ons & libraries
Get Nh Investment And Securities 1p Fundamental Data
Nh Investment And Securities 1p Fundamental data includes:
- Net Revenue: 9 059 961 M
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-24
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nh Investment And Securities 1p News
New
ImmunoForge Receives IND Approval for Phase 2 Clinical Trial of 'Pemziviptadil' for DMD Cardiomyopathy Treatment from FDA, and KF1601, a chronic myeloid leukemia treatment, phase 1 clinical trial IND approved by MFDS
SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ -- ImmunoForge announced that it has received approval for the Phase 2 clinical trial IND for 'Pemziviptadil (development code name PF1804),' a treatment...
UNLIMEAT Kimbap Products Now Available via DoorDash's DashMart
- UNLIMEAT is now being sold on DoorDash's DashMart, the company's online convenience store, to make UNLIMEAT Kimbap available nationwide. LOS ANGELES, May 30, 2024 /PRNewswire/ -- Frozen kimbap ha...
UNLIMEAT Pulled Pork Wrap Now Available at All Starbucks Stores in HK
Starting April 16th, Starbucks launched UNLIMEAT pulled pork wrap as its newest plant-based option. UNLIMEAT's Starbucks collaboration is the most recent in a series of collaborations between UNLIMEA...
ImmunoForge Doses First Patient in Phase 2 Clinical Trial of Froniglutide for Dermatomyositis/Polymyositis
SEOUL, South Korea, Oct. 17, 2023 /PRNewswire/ -- ImmunoForge today announced that it has dosed the first patient in its Phase 2 clinical trial to evaluate the efficacy, safety, and pharmacokinetic pr...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
